Zilver PTX与Eluvia支架治疗股腘动脉病变的真实世界一年结局:REALDES研究
这项多中心前瞻性观察研究在8家日本医院比较Zilver PTX与Eluvia支架治疗股腘动脉原发病变的一年结局。共200条肢体(Zilver PTX 96条,Eluvia 104条),12个月一期通畅率分别为84.9%和88.1%(log-rank p=0.417),临床驱动靶病变血运重建豁免率分别为88.8%和90.9%(log-rank p=0.812),两组无显著差异。
要点
- Zilver PTX组病变长度长于Eluvia组(185.7±92.0 mm vs 160.0±98.5 mm,p=0.030)。
- 12个月一期通畅率Zilver PTX组84.9% vs Eluvia组88.1%(log-rank p=0.417)。
- 12个月临床驱动TLR豁免率Zilver PTX组88.8% vs Eluvia组90.9%(log-rank p=0.812)。
核心结论
- 在真实世界治疗股腘动脉外周动脉疾病患者中,Zilver PTX与Eluvia支架在12个月一期通畅率和临床驱动靶病变血运重建豁免率方面无显著差异。
- 作者指出这是首项揭示在进行了适当血管准备时Zilver PTX与Eluvia在真实世界实践中结果相似的研究;但Eluvia支架的再狭窄类型可能与Zilver PTX支架不同;因此本研究结果可能影响常规临床实践中股腘动脉病变药物洗脱支架的选择。
研究设计与样本
- 多中心、前瞻性、观察性研究,2019年2月至2020年9月在8家日本医院纳入200条原生股腘动脉病变肢体,接受Zilver PTX(96条肢体)或Eluvia(104条肢体)治疗。
- 主要结局指标为12个月一期通畅率,定义为收缩期峰值流速比≤2.4且无临床驱动靶病变血运重建或基于血管造影发现的狭窄≤50%。
主要发现
- Zilver PTX组与Eluvia组基线临床和病变特征大致相当(全部分析肢体中约30%表现为慢性肢体威胁性缺血,约60%为TASC II C-D级,约半数有完全闭塞),但Zilver PTX组病变长度更长(185.7±92.0 mm vs 160.0±98.5 mm,p=0.030)。
- 12个月一期通畅率的Kaplan-Meier估计值Zilver PTX组为84.9%,Eluvia组为88.1%(log-rank p=0.417)。
- 临床驱动靶病变血运重建豁免率Zilver PTX组为88.8%,Eluvia组为90.9%(log-rank p=0.812)。
关键数值与推荐
- 12个月一期通畅率Kaplan-Meier估计值:Zilver PTX组84.9% vs Eluvia组88.1%(log-rank p=0.417)。
- 临床驱动靶病变血运重建豁免率:Zilver PTX组88.8% vs Eluvia组90.9%(log-rank p=0.812)。
- 病变长度:Zilver PTX组185.7±92.0 mm vs Eluvia组160.0±98.5 mm(p=0.030)。
临床怎么用
- 作者认为,在进行了适当血管准备时,Zilver PTX与Eluvia在真实世界实践中结果相似,但Eluvia支架的再狭窄类型可能与Zilver PTX支架不同。
- 作者指出本研究结果可能影响常规临床实践中股腘动脉病变药物洗脱支架的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This multicenter, prospective, observational study aimed to compare Zilver PTX and Eluvia stents in real-world settings for treating femoropopliteal lesions as the differences in the 1-year outcomes of these stents have not been elucidated. MATERIALS AND METHODS: Overall, 200 limbs with native femoropopliteal artery disease were treated with Zilver PTX (96 limbs) or Eluvia (104 limbs) at 8 Japanese hospitals between February 2019 and September 2020. The primary outcome measure of this study was primary patency at 12 months, defined as a peak systolic velocity ratio of ≤2.4, without clinically-driven target lesion revascularization (TLR) or stenosis ≤50% based on angiographic findings. RESULTS: The baseline clinical and lesion characteristics of Zilver PTX and Eluvia groups were roughly comparable (of all limbs analyzed, approximately 30% presented with critical limb-threatening ischemia, approximately 60% presented with Trans-Atlantic Inter-Society Consensus II C-D, and approximately half had total occlusion), except for the longer lesion lengths in the Zilver PTX group (185.7±92.0 mm vs 160.0±98.5 mm, p=0.030). The Kaplan-Meier estimates of primary patency at 12 months were 84.9% and 88.1% for Zilver PTX and Eluvia, respectively (log-rank p=0.417). Freedom from clinically-driven TLR rates were 88.8% and 90.9% for Zilver PTX and Eluvia, respectively (log-rank p=0.812). CONCLUSIONS: The results of the Zilver PTX and Eluvia stents were not different regarding primary patency and freedom from clinically-driven TLR at 12 months after treating patients with femoropopliteal peripheral artery disease in real-world settings.Clinical ImpactThis is the first study to reveal that the Zilver PTX and Eluvia have similar results in real-world practice when the proper vessel preparation is performed. However, the type of restenosis in the Eluvia stent may differ from that in the Zilver PTX stent. Therefore, the results of this study may influence the selection of DES for femoropopliteal lesions in routine clinical practice.
引用
- Shibata T, Iba Y, Shingaki M, et al. One Year Outcomes of Zilver PTX Versus Eluvia for Femoropopliteal Disease in Real-World Practice: REALDES Study. J Endovasc Ther. 2023. PMID: 37291881. doi:10.1177/15266028231179861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。